2
Clinical Trials associated with Anti-PD1 Antibody-activated TILs(Sun Yat-sen University) / Unknown statusPhase 1/2IIT A Phase I/II Study of Combination of Anti-Programmed Cell Death Protein1 (Anti-PD1) Antibody-activated Autologous Tumor Infiltrating Lymphocytes (TILs) and Chemotherapy in the Treatment of Stage II-IIIA Non-small Cell Lung Cancer
This study was a phase I/II trial initiated by the investigator to evaluate the safety and tolerability of anti-PD-1 antibody-activated TILs combined with adjuvant chemotherapy in participants with stage II-IIIA non-small cell lung cancer. 20 participants were enrolled and anti-PD-1 antibody-activated TILs was infused into participants after the final cycle chemotherapy to assess the safety and disease-free survival.
/ Unknown statusPhase 1/2IIT A Phase I/II Study of Combination of Anti-Programmed Cell Death Protein 1(Anti-PD1) Antibody-activated Autologous Tumor Infiltrating Lymphocytes (TILs) and Chemotherapy in the Treatment of Stage III Colorectal Cancer.
This study was a phase I/II trial initiated by the investigator to evaluate the safety and tolerability of anti-programmed cell death protein 1 (anti-PD1) antibody-activated autologous tumor-infiltrating lymphocytes (TILs) combined with adjuvant chemotherapy in participants with stage III colon cancer. Twenty participants were enrolled and anti-PD1 antibody-activated TILs was infused into participants after the final of adjuvant chemotherapy to assess the safety and 3-year disease-free survival.
100 Clinical Results associated with Anti-PD1 Antibody-activated TILs(Sun Yat-sen University)
100 Translational Medicine associated with Anti-PD1 Antibody-activated TILs(Sun Yat-sen University)
100 Patents (Medical) associated with Anti-PD1 Antibody-activated TILs(Sun Yat-sen University)
100 Deals associated with Anti-PD1 Antibody-activated TILs(Sun Yat-sen University)